Immuno-Oncology (IO) - Thematic Intelligence

Immuno-Oncology (IO) - Thematic Intelligence

Summary

This report includes coverage of immuno-oncology overview, trends, value chain, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field.

The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation to remain the most valuable IO sector. 2022–23 has seen some IO success, but no major IO breakthrough has happened. Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.

Key Highlights

Forecast includes 8 countries
Forecast covers 2022-2028
Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Scope

• This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

OBTAIN IMMUNO-ONCOLOGY MARKET ASSESSMENT AND FORECAST ACROSS MULTIPLE REGIONS

GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as -

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?